<code id='B1BC5097D6'></code><style id='B1BC5097D6'></style>
    • <acronym id='B1BC5097D6'></acronym>
      <center id='B1BC5097D6'><center id='B1BC5097D6'><tfoot id='B1BC5097D6'></tfoot></center><abbr id='B1BC5097D6'><dir id='B1BC5097D6'><tfoot id='B1BC5097D6'></tfoot><noframes id='B1BC5097D6'>

    • <optgroup id='B1BC5097D6'><strike id='B1BC5097D6'><sup id='B1BC5097D6'></sup></strike><code id='B1BC5097D6'></code></optgroup>
        1. <b id='B1BC5097D6'><label id='B1BC5097D6'><select id='B1BC5097D6'><dt id='B1BC5097D6'><span id='B1BC5097D6'></span></dt></select></label></b><u id='B1BC5097D6'></u>
          <i id='B1BC5097D6'><strike id='B1BC5097D6'><tt id='B1BC5097D6'><pre id='B1BC5097D6'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:Wikipedia    - browse:19
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand. Adobe

          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

          advertisement

          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge